New Immune-Targeting injection tested in healthy people for first time
NCT ID NCT07058779
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests a single dose of SSS55 injection in 26 healthy adults in China. The main goal is to check if it is safe and how the body handles it. Researchers will also look at how it affects the immune system. This is a first step before testing it in people with diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SSS55 injection (targets complement C3b, a part of the immune system)
- What this could lead to
- If safe, this could pave the way for future studies of SSS55 in diseases where the immune system attacks the body, like certain autoimmune conditions.
- What could go wrong
- This is a very early Phase 1 trial in only 26 healthy people, so it cannot tell us if SSS55 works for any disease. Side effects are unknown and may occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SAFETY ISSUES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Decades-Old drug reverse pancreatic scarring?
- Could KP405 offer a new way to tackle Parkinson's?
- Stem cells injected into heart arteries may help repair damage after a heart attack
- First human trial of ETD-001 gel begins safety testing
- New hope for transplant patients with hepatitis b: safer drug switch under study
- New vaginal ring aims to prevent HIV and pregnancy in one device